MODELLING A COST-OF-ILLNESS STUDY TO EVALUATE THE BURDEN OF INFLUENZA IN ITALY
Author(s)
Aimola A, Gianfrate F, Health Economics Department, Glaxo Wellcome, Verona, Italy
Even though it is widely recognised that influenza is a serious disease that causes significant consequences in terms of morbidity and mortality, implying considerable healthcare costs and loss of productivity, there is a lack of data about the economic impact of an influenza epidemic in Italy. OBJECTIVES: The aim of this study was to estimate the social cost of a normal influenza epidemic in Italy using a generic algorithm for influenza outbreak and treatment. METHODS: Referring to the demographic characteristics of the population, to the published literature and to the epidemiological data (influenza season 1998/99), a simulation of the impact of a real influenza epidemic was run. The health service use and unit costs were estimated from standard data sources. RESULTS: The average direct costs of influenza per person in Italy were lit. 68,000 ($US 36), for the overall population, and lit. 155,000 ($US 82.26) for a high-risk patient; the average indirect costs of influenza per working patient were lit. 569,000 ($US 301.97). Hence, the total cost of a case of influenza in Italy was about lit. 637,000 ($US 338). In general, around 90% of total costs consisted of indirect costs. Costs are sensitive to changes in the rate of hospitalisation and to changes in the proportion of the active population. CONCLUSIONS: Cost-of-illness studies should be as observational to reflect the real world. Nevertheless, if relevant data are not available, a suitable model, which uses reliable data, can give consistent estimates of the cost of influenza in Italy. This kind of models may help decision-makers heighten awareness of the burden of influenza and design prevention and treatment strategies.
Conference/Value in Health Info
2000-05, ISPOR 2000, Arlington, VA, USA
Value in Health, Vol. 3, No. 2 (March/April 2000)
Code
PHV3
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)